HPK1-IN-69
HPK1-IN-69 is an orally active HPK1 inhibitor with an IC50 of 1.7 nM. HPK1-IN-69 inhibits the HPK1-mediated TCR signaling pathway, reduces the phosphorylation level of SLP76, and promotes the release of IL-2. HPK1-IN-69 exhibits in vivo anti-tumor activity in mouse models. HPK1-IN-69 can be used for the research of colorectal cancer and MC38 syngeneic tumors.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3095423-83-6
- 分子式: C22H24N8O
- 分子量:416.48
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MAP4K アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
HPK1 |
IL-2 |
体外実験
HPK1-IN-69 (compound 53) (0-300 nM; 2 h pre-incubation) inhibits CD3/CD28-induced phosphorylation of SLP76 in Jurkat T cells in a dose-dependent manner, with an IC50 of 23.1 nM for pSLP76[1].
HPK1-IN-69 (0-1000 nM; 1 h pre-incubation) dose-dependently enhances CD3/CD28-induced IL-2 release in Jurkat T cells (EC50 = 29.9 nM) and hPBMCs, and reverses PGE2-mediated inhibition of IL-2[1].
HPK1-IN-69 (0-60 min) exhibits favorable metabolic stability in mouse and human liver microsomes, with a half-life of over 30 min[1].
HPK1-IN-69 exhibits weak inhibitory effects on human CYP isoenzymes, with IC50 values ranging from 6.1 μM to >50 μM, suggesting that it has a specific safety window regarding CYP interactions[1].
HPK1-IN-69 exhibits relatively low inhibitory activity against hERG channels, with an IC50 of 7.92 μM, suggesting a low risk of cardiotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat T cells
-
Concentration:0, 1, 3, 10, 30, 100, 300 nM
-
Incubation Time:2 h (pre-incubation prior to 10 min CD3/CD28 stimulation)
-
Result:Dose-dependently inhibited SLP76 phosphorylation in Jurkat cells, with a cellular IC50 of 23.1 nM for pSLP76 inhibition.
Parmacokinetics
体内実験
HPK1-IN-69 (15-60 mg/kg; i.p./p.o.; twice daily; for 21 consecutive days) exhibits potent anti-tumor efficacy in the MC38 colorectal cancer mouse model, with a tumor growth inhibition (TGI) rate of 64% at the oral dose of 60 mg/kg; it also shows synergistic activity in combination with anti-PD-1 antibody, achieving a TGI of 77%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 18-22 g, 4-5 weeks old, subcutaneous inoculation of CT26 cells)[1]
-
Dosage:15 mg/kg; 30 mg/kg; 30 mg/kg
-
Administration:i.p.; twice daily; 17 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 36% at 15 mg/kg.
Achieved a TGI of 62% at 30 mg/kg, with significantly reduced tumor weight relative to the model group.
Achieved a TGI of 75% when combined with anti-PD-1 antibody.
Enhanced CD8+ T-cell infiltration into tumor tissue in a dose-dependent manner.
Caused no significant body weight loss or major organ damage.
化学情報
-
CAS 番号 3095423-83-6
-
分子量 416.48
-
分子式 C22H24N8O
-
SMILES
CN1CCN(CC1)C2=CC=C(C=C2C#N)C3=CN=C(N)C(OCC4=CC=NC(N)=C4)=N3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)